+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Genitourinary Partnering 2010-2021: Deal Trends, Players and Financials

  • ID: 2229056
  • Report
  • June 2021
  • Region: Global
  • 400 Pages
  • CurrentPartnering


  • A1M Pharma
  • CamelBak
  • French Investment Fund
  • MD Anderson Cancer Center
  • Pfizer
  • Siemens Healthineers
Global Genitourinary Partnering 2010 to 2021 provides the full collection of Genitourinary disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
  • Trends in Genitourinary partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genitourinary partnering agreement structure
  • Genitourinary partnering contract documents
  • Top Genitourinary deals by value
  • Most active Genitourinary dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genitourinary deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genitourinary deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2010. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.

Report scope

Global Genitourinary Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.

Global Genitourinary Partnering 2010 to 2021 includes:
  • Trends in Genitourinary dealmaking in the biopharma industry since 2010
  • Analysis of Genitourinary deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genitourinary deal contract documents
  • Comprehensive access to over 570 Genitourinary deal records
  • The leading Genitourinary deals by value since 2010
  • Most active Genitourinary dealmakers since 2010
The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie's disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.

In Global Genitourinary Partnering 2010 to 2021, available deals and contracts are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genitourinary Partnering 2010 to 2021 report provides comprehensive access to available deals and contract documents for over 570 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise Genitourinary rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Note: Product cover images may vary from those shown


  • A1M Pharma
  • CamelBak
  • French Investment Fund
  • MD Anderson Cancer Center
  • Pfizer
  • Siemens Healthineers
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genitourinary dealmaking
2.1. Introduction
2.2. Genitourinary partnering over the years
2.3. Genitourinary partnering by deal type
2.4. Genitourinary partnering by industry sector
2.5. Genitourinary partnering by stage of development
2.6. Genitourinary partnering by technology type
2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering
3.1. Introduction
3.2. Disclosed financials terms for Genitourinary partnering
3.3. Genitourinary partnering headline values
3.4. Genitourinary deal upfront payments
3.5. Genitourinary deal milestone payments
3.6. Genitourinary royalty rates

Chapter 4 - Leading Genitourinary deals and dealmakers
4.1. Introduction
4.2. Most active in Genitourinary partnering
4.3. List of most active dealmakers in Genitourinary
4.4. Top Genitourinary deals by value

Chapter 5 - Genitourinary contract document directory
5.1. Introduction
5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genitourinary therapeutic target

Appendix 1 - Directory of Genitourinary deals by company A-Z 2010 to 2021
Appendix 2 - Directory of Genitourinary deals by deal type 2010 to 2021
Appendix 3 - Directory of Genitourinary deals by stage of development 2010 to 2021
Appendix 4 - Directory of Genitourinary deals by technology type 2010 to 2021
Further reading on dealmaking
Deal type definitions

Table of figures
Figure 1: Genitourinary partnering since 2010
Figure 2: Genitourinary partnering by deal type since 2010
Figure 3: Genitourinary partnering by industry sector since 2010
Figure 4: Genitourinary partnering by stage of development since 2010
Figure 5: Genitourinary partnering by technology type since 2010
Figure 6: Genitourinary partnering by indication since 2010
Figure 7: Genitourinary deals with a headline value
Figure 8: Genitourinary deals with upfront payment values
Figure 9: Genitourinary deals with milestone payment
Figure 10: Genitourinary deals with royalty rates
Figure 11: Active Genitourinary dealmaking activity- 2010 to 2021
Figure 12: Top Genitourinary deals by value since 2010
Note: Product cover images may vary from those shown
  • A1M Pharma
  • Acerus
  • Aceto Corporation
  • Acon Labs
  • Acurx Pharmaceuticals
  • AEterna Zentaris
  • Aetna
  • Akebia Therapeutics
  • AKESOgen
  • Alivio Therapeutics
  • Allegis Holdings
  • Allergan
  • Alnylam Pharmaceuticals
  • AM-Pharma
  • American Diabetes Association
  • American Medical Systems
  • Amgen
  • Angion Biomedica
  • Anthem Bluecross
  • Anthera Pharmaceuticals
  • Applied Medical
  • Aquinox Pharmaceuticals
  • Arch Biopartners
  • Ardelyx
  • Arena Pharmaceuticals
  • Arkray USA
  • Arrevus
  • Ascend Therapeutics
  • Astellas Pharma
  • Astellas Pharma US
  • AstraZeneca
  • Astute Medical
  • Atara Biotherapeutics
  • Aytu BioScience
  • Aziyo Biologics
  • Baxter International
  • Beckman Coulter
  • Beijing Leadman Biochemistry
  • BioCad Holding
  • BioDerm
  • bioMerieux
  • BioPorto
  • BioSerenity
  • BioVectra
  • Boehringer Ingelheim
  • Boston Scientific
  • Bridge Medicines
  • Brigham and Women's Hospital
  • Caldera Pharmaceuticals
  • CamelBak
  • Cara Therapeutics
  • CARB-X
  • Cardio Renal Society of America
  • Casper Pharma
  • Celtic Biotech
  • ChemoCentryx
  • CJ Corp
  • Cleveland Clinic
  • Clinipace Worldwide
  • Codexis
  • Cogentix Medical
  • Collaborative Study Group
  • Columbia University
  • Control Flo Medical
  • Cook Biotech
  • Cook Medical
  • Corino Therapeutics
  • Covance
  • CrossBay Medical
  • Cryolife
  • Cumberland Pharmaceuticals
  • CytoSorbents
  • Dalton Pharma Services
  • DaVita HealthCare Partners
  • Debiotech
  • Degania Silicone
  • Dignify Therapeutics
  • DILIsym Services
  • Dimerix Biosciences
  • DiscoveryBioMed
  • Distal Access
  • Duchesnay
  • Ecole Polytechnique Federale de Lausanne
  • EirGen Pharma
  • Elexopharm
  • EMD Serono
  • Endo International
  • Epigen Biosciences
  • Erasmus University Medical Center
  • Everest Medicines
  • Evestra
  • Evotec
  • Fedora Pharmaceuticals
  • Ferring Pharmaceuticals
  • Fimbrion Therapeutics
  • FirstString Research
  • Fortress Biotech
  • Fosun Pharmaceutical
  • Fougera Pharmaceuticals
  • Foundation for International Urogynecological Assistance
  • Fred Hutchinson Cancer Research Center
  • French Investment Fund
  • Frenova Renal Research
  • Fresenius Medical Care
  • FSC Laboratories
  • Gebro Pharma
  • Gedeon Richter
  • Geisinger Medical Center
  • GeneNews
  • Genewiz
  • Genzyme
  • George Washington University
  • GlaxoSmithKline
  • Goldfinch Bio
  • Government of Canada
  • Hainan Sihuan Pharmaceutical
  • Hancock Jaffe Laboratories
  • Harvard Stem Cell Institute
  • Healthy.io
  • Helix BioPharma
  • HemoCleanse
  • Hitachi Medical Systems Europe
  • Humana
  • Hydra Biosciences
  • HydroCision
  • Icahn School of Medicine at Mount Sinai
  • Idera Pharmaceuticals
  • ImpediMed
  • Imprimis Pharmaceuticals
  • Innovation Network Corporation
  • Innovative Diagnostic Laboratory
  • Innovus Pharmaceuticals
  • Invitae
  • InVivo
  • Ion Channel Innovations
  • Ionis Pharmaceuticals
  • Itochu
  • Janssen Research & Development
  • Japan Tobacco
  • Johns Hopkins University
  • Juventas Therapeutics
  • Karolinska Institute
  • Keryx Biopharmaceuticals
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • L&F Research
  • Laboratorios Q Pharma
  • La Jolla Pharmaceutical
  • Lavasta Pharma
  • LeMaitre Vascular
  • Lupus Foundation of America (LFA)
  • Luqa Pharmaceuticals
  • Mannin Research
  • Mar Cor Purification
  • Mariel Therapeutics
  • Massachusetts General Hospital
  • Mayo Clinic
  • MD Anderson Cancer Center
  • MedCom
  • MediBeacon
  • MediGene
  • Medinova
  • Medipal Holdings
  • Medison Pharma
  • Medline Industries
  • Medpace
  • Medtronic
  • Meiji Seika
  • Melinta Therapeutics
  • Memorial Sloan Kettering Cancer Center
  • Menarini
  • Merck Sharpe & Dohme
  • Metabolon
  • Metamark Genetics
  • Methuselah Foundation
  • MicrobeDx
  • Minnesota Medical
  • Mironid
  • Mission Pharmacal
  • Mitobridge
  • Mitsubishi Tanabe Pharma
  • Murdoch Childrens Research Institute
  • NacuGen Therapeutics
  • Nashville Biosciences
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Child Health and Human Development
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • National Kidney Registry
  • NCPC GeneTech
  • NephCure Kidney International
  • Nephrogenex
  • Nephros
  • Neptune Technologies & Bioressources
  • Nestle Health Science
  • NeuralStem
  • New York University School of Medicine
  • Nikkiso
  • Norgenix Pharmaceuticals
  • Noventure
  • Novo Nordisk
  • Nxstage Medical
  • OPKO Health
  • Organovo
  • Ortho-Clinical Diagnostics
  • Otsuka
  • Outpost Medicine
  • Oxford Immunotec
  • Palette Life Sciences
  • Pansend
  • Par Pharmaceutical
  • Patheon N.V.
  • Perlara
  • Pfizer
  • Phadia
  • Pharmacological research Institute Mario Negri
  • PharmaSwiss
  • Pharmstandard
  • Phosphate Therapeutics
  • Pierre Fabre
  • Piramal
  • PlugMed
  • Poiesis Medical
  • PPD
  • Precision Image Analysis
  • Premier Inc
  • Procept BioRobotics
  • Promepla
  • Promethera Biosciences
  • Prometic Life Sciences
  • Proteomics International
  • Purdue Pharma
  • PX Therapeutics
  • Q BioMed
  • Quebec Urological Association Foundation
  • Quimica Europea
  • Rambam Medical Center
  • RaNA Therapeutics
  • Rebiotix
  • Recordati
  • Recordati Espana
  • ReCor Medical
  • Relief Therapeutics
  • RenalSense
  • RenalytixAI
  • Renovar
  • RENX AI Labs
  • Resverlogix
  • Retrophin
  • RFSU
  • Rising Pharmaceuticals
  • Rockwell Medical
  • ROi (Resource Optimization & Innovation)
  • Roivant Sciences
  • Sanofi
  • Satellite Healthcare
  • Scanwell Health
  • Scohia Pharma
  • Shenzhen Hepalink Pharmaceutical
  • Shenzhen University
  • Shionogi
  • Shire Laboratories
  • Siemens Healthineers
  • Sinovant Sciences
  • SOM Biotech
  • Sonacare Medical
  • South Coast Specialty Compounding
  • Specialty Renal Products
  • Sphingotec
  • Stanford University
  • Stem Cell Network
  • Stryker
  • Swedish Orphan Biovitrum
  • Symic Biomedical
  • Syneron
  • Takeda Pharmaceutical
  • TARIS Biomedical
  • Teijin
  • TekMed
  • Teleflex
  • The Medicines Company
  • toSense
  • Tufts Medical Center
  • Tulane University
  • twoXAR
  • Unilife
  • UniQuest
  • United Medical Systems (UMS)
  • University of Bristol
  • University of California
  • San Diego
  • University of California Los Angeles
  • University of Cambridge
  • University of Michigan
  • University of Sheffield
  • University of South Carolina
  • University of South Carolina Research Foundation
  • Urigen
  • UroGen Pharma
  • Urovant Sciences
  • USMD Holdings
  • Vanderbilt University
  • Variant Pharmaceuticals
  • VenatoRx
  • Vifor-Fresenius Medical Care Renal Pharma Ltd
  • Vifor Pharma
  • Viracor-IBT
  • ViveBio
  • Vivione Biosciences
  • Vizient
  • Womens Choice Pharmaceuticals
  • Wuxi Apptec Laboratory Services
  • Xisle Pharma Ventures Trust
  • Xortx Pharma
  • Yale University
  • Yung Shin Pharm
  • Zenalux Biomedical
  • Zenyaku Kogyo
Note: Product cover images may vary from those shown
  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.